Target items and results after full-scale introduction (2019.4~)

We show targeted medicines and medical devices and results of cost-effectiveness evaluation after April 2019.

FY 2021

ID Brand name Generic name Category Designated day Status
C2H2101 Emgality Galcanezumab H1 4/14/2021 In progress
C2H2102 Yescarta Axicabtagene ciloleucel H5 4/14/2021 -
C2H2103 Polivy Polatuzumab Vedotin H1 5/12/2021 In progress
C2H2104

Darzquro

Daratumumab
Vorhyaluronidase Alfa
H1 5/12/2021 In progress
C2H2105

Arikayce

Amikacin sulfate H1 5/12/2021 In progress
C2H2106 Breyanzi Lisocabtagene maraleucel H5 5/12/2021 -
C2H2107 Verquvo Vericiguat H5 8/4/2021 -
C2H2108 Ajovy Fremanezumab (Genetical Recombination) H5 8/4/2021 -
C2H2109 Aimovig Erenumab (Genetical Recombination) H5 8/4/2021 -
C2H2110 Revestive Teduglutide (Genetical Recombination) H2 8/4/2021 In progress
C2H2111 Veklury Remdesivir H1 8/4/2021 In progress

FY 2020

ID Brand name Generic name Category Designated day Status
C2H2001 Noxafil Posaconazole H1 4/8/2020 In progress
C2H2002 Cabometyx Cabozantinib H1 5/13/2020 In progress
C2H2003 Enhertu Trastuzumab Deruxtecan (Genetical Recombination) H1 5/13/2020 In progress
C2H2004 Zolgensma Onasemnogene abeparvovec H3 5/13/2020 In progress
C2H2005 Entresto Sacubitril Valsartan H5 8/19/2020 -
C2H2006

Enerzair

Indacaterol,
Glycopyrronium,
Mometasone
H5 8/19/2020 -
C2H2007

Rybelsus

Semaglutide (Genetical Recombination) H1 11/11/2020 In progress
C2H2008

Trelegy200

Fluticasone, Umeclidinium, Vilanterol H5 2/10/2021 -

FY 2019

ID Brand name Generic name Category Designated day Status
C2H1901 Trelegy Fluticasone, Umeclidinium, Vilanterol H1 05/15/2019 Completed
C2H1902 Kymriah Tisagenlecleucel H3 05/15/2019 Completed
C2H1903 Ultomiris Ravulizumab H1 08/28/2019 Completed
C2H1904 Breztri Budesonide, Glycopyrronium, Formoterol H5 08/28/2019 -
C2H1905 Trintellix Vortioxetine H1 11/13/2019 Completed
C2H1906 Coralan Ivabradine H2 11/13/2019 Completed